The Conversation (0)
Pediapharm Inc. (TSXV:PDP) and Merz Pharma Canada, Ltd. announced an agreement regarding the Canadian rights to CUVPOSA™, or glycopyrrolate oral solution for pediatric chronic severe drooling, or sialorrhea associated with neurologic conditions such as cerebral palsy. Pediapharm plans to register the product with Health Canada this year and, if approved, expects to launch CUVPOSA™ in 2015.
Pediapharm Inc. (TSXV:PDP) and Merz Pharma Canada, Ltd. announced an agreement regarding the Canadian rights to CUVPOSA™, or glycopyrrolate oral solution for pediatric chronic severe drooling. Also known as sialorrhea, pediatric chronic severe drooling sometimes occurs with neurologic conditions such as cerebral palsy. Pediapharm plans to register the product with Health Canada this year and, if approved, expects to launch CUVPOSA™ in 2015.
As quoted in the press release:
CUVPOSA™ was approved by the FDA in July 2010 and has been commercially available in the U.S. since April 2011. It is the only FDA-approved treatment to reduce chronic severe drooling in pediatric patients (aged 3-16) with neurologic conditions associated with problem drooling. Sialorrhea is a common problem for individuals with neurologic conditions, especially children with cerebral palsy.
Pediapharm CEO, Sylvain Chrétien, said:
CUVPOSA™ will be an important addition to our portfolio of innovative products and further strengthens our commitment to becoming the recognized leader in the treatment of diseases and conditions affecting children.
Click here to read the Pediapharm Inc. (TSXV:PDP) press release
